Synthetic OpenEMR / FHIR-style transport

Annotated oncology EHR example

Synthetic annotated oncology EHR and claims transport with source trace, treatment-failure signals, ECOG, and data-quality flags.

Open JSON transport Treatment failure concept ECOG score concept
Patient token
SYN-ONC-0007
Cancer
Malignant neoplasm of upper lobe, right bronchus or lung
Stage / biomarker
Stage IVB; EGFR exon 19 deletion
Linkage confidence
0.94
Longitudinal record

Timeline

DiagnosisStage IVB
Ambulatorynew lung mass workup
Creatinine0.9 mg/dL
Start LOT 1osimertinib
ECOG Performance Status1
Ambulatorysystemic therapy start
CEA21.4 ng/mL
Emergencydyspnea and pleural effusion
imaging-summaryprogressive disease
Stop therapyradiographic progression / non-response
ECOG Performance Status2
Candidate failure dateprobable treatment failure / non-response
Start LOT 2carboplatin + pemetrexed + pembrolizumab
Constructed endpoint

Treatment failure evidence

Classification: probable treatment failure / non-response; certainty: moderate; candidate date: 2024-08-05.

  • medrx-1MedicationRequest stopped for progression
  • medrx-2New line of therapy started within 7 days
  • img-1Imaging summary says progressive disease
  • ecog-2ECOG worsened from 1 to 2
  • enc-3Emergency encounter for dyspnea and pleural effusion
Baseline and follow-up

Patient context

Age at index66
Sexfemale
Race / ethnicityBlack or African American; Not Hispanic or Latino
RegionUS-South
Payer typecommercial
Subscriber / membersub_44fd19 / mem_772ac1
Treatment and observations
LOTDrugStartStopStatus
1osimertinib2024-02-092024-08-05radiographic progression / non-response
2carboplatin + pemetrexed + pembrolizumab2024-08-12activeactive
DateObservationLOINCValueRWE use
2024-02-05Creatinine2160-00.9Baseline renal covariate.
2024-07-15CEA2039-621.4Tumor-marker progression support.
2024-02-09ECOG Performance Status89247-11Baseline functional-status covariate.
2024-08-05ECOG Performance Status89247-12Clinical deterioration and endpoint-support signal.
2024-08-01imaging-summaryprogressive diseaseClinical response component; not RECIST-confirmed unless source report is available.
Source trace
Derived fieldTrace
line of therapyMedicationRequest sequence and stop/start dates
treatment failure non responseMedication status reason, imaging summary, ECOG change, next-line therapy, and ED utilization
claimsPayer extract line-level claims linked to encounter IDs
ecogStructured observation using LOINC 89247-1
Data quality flags
FlagSeverityAffects
synthetic_recordinfoall fields
date_shiftedinfocalendar-time interpretation
imaging_not_recist_confirmedmediumtreatment_failure_non_response
claims_ehr_linkage_probabilisticmediumclaims_linkage
oral_adherence_unobservedmediumosimertinib exposure duration
Claims linkage
DateSettingClaimEncounter
2024-02-09outpatientclaim_77aaenc-2
2024-07-21emergencyclaim_91fdenc-3
Model references
  1. OpenEMR FHIR API documentation
  2. HL7 FHIR R4 Encounter
  3. HL7 FHIR R4 Condition
  4. HL7 FHIR R4 MedicationRequest
  5. HL7 FHIR R4 Observation
  6. mCODE ECOG Performance Status
  7. FDA Real-World Data guidance
JSON transport
{
  "transport_meta": {
    "schema": "rwednesdays.synthetic_oncology_ehr.v0.1",
    "style": "OpenEMR/FHIR-R4-like longitudinal patient bundle",
    "synthetic": true,
    "date_shifted": true,
    "contains_phi": false,
    "generated_at": "2026-06-18T12:00:00-04:00",
    "license_note": "Synthetic example for methods education only; not medical advice and not patient data."
  },
  "patient": {
    "synthetic_patient_id": "SYN-ONC-0007",
    "pseudonymized_ids": {
      "ehr_patient_token": "ehrtok_9b7a2d",
      "claims_patient_token": "clmtok_51fd90",
      "linkage_confidence": 0.94
    },
    "demographics": {
      "age_at_index": 66,
      "sex": "female",
      "race": "Black or African American",
      "ethnicity": "Not Hispanic or Latino",
      "region": "US-South"
    },
    "_rwe": "Cohort eligibility, baseline covariates, subgroup checks, and linkage denominator."
  },
  "diagnoses": [
    {
      "id": "cond-1",
      "resource_type": "Condition",
      "code": {
        "system": "ICD-10-CM",
        "code": "C34.11",
        "display": "Malignant neoplasm of upper lobe, right bronchus or lung"
      },
      "clinical_status": "active",
      "verification_status": "confirmed",
      "onset_date": "2024-01-18",
      "stage_at_diagnosis": "Stage IVB",
      "biomarkers": [
        {
          "name": "EGFR exon 19 deletion",
          "result": "positive",
          "date": "2024-02-02"
        }
      ],
      "_rwe": "Incident cancer diagnosis, disease site, stage, and molecular eligibility subgroup."
    }
  ],
  "encounters": [
    {
      "id": "enc-1",
      "resource_type": "Encounter",
      "class": "ambulatory",
      "date": "2024-01-18",
      "provider_type": "oncology",
      "reason": "new lung mass workup",
      "_rwe": "Care setting and index workup."
    },
    {
      "id": "enc-2",
      "resource_type": "Encounter",
      "class": "ambulatory",
      "date": "2024-02-09",
      "provider_type": "medical oncology",
      "reason": "systemic therapy start",
      "_rwe": "Index date anchor."
    },
    {
      "id": "enc-3",
      "resource_type": "Encounter",
      "class": "emergency",
      "date": "2024-07-21",
      "reason": "dyspnea and pleural effusion",
      "_rwe": "Acute utilization and possible progression signal."
    }
  ],
  "medications": [
    {
      "id": "medrx-1",
      "resource_type": "MedicationRequest",
      "drug": "osimertinib",
      "rxnorm": "1723758",
      "intent": "order",
      "status": "stopped",
      "start_date": "2024-02-09",
      "stop_date": "2024-08-05",
      "dose": "80 mg oral daily",
      "status_reason": "radiographic progression / non-response",
      "line_of_therapy": 1,
      "_rwe": "Exposure, line-of-therapy start/stop, and treatment discontinuation signal."
    },
    {
      "id": "medrx-2",
      "resource_type": "MedicationRequest",
      "drug": "carboplatin + pemetrexed + pembrolizumab",
      "status": "active",
      "start_date": "2024-08-12",
      "line_of_therapy": 2,
      "_rwe": "Post-failure regimen switch and next-line therapy."
    }
  ],
  "observations": [
    {
      "id": "lab-1",
      "resource_type": "Observation",
      "category": "laboratory",
      "loinc": "2160-0",
      "name": "Creatinine",
      "date": "2024-02-05",
      "value": 0.9,
      "unit": "mg/dL",
      "_rwe": "Baseline renal covariate."
    },
    {
      "id": "lab-2",
      "resource_type": "Observation",
      "category": "laboratory",
      "loinc": "2039-6",
      "name": "CEA",
      "date": "2024-07-15",
      "value": 21.4,
      "unit": "ng/mL",
      "trend": "rising from 8.2",
      "_rwe": "Tumor-marker progression support."
    },
    {
      "id": "ecog-1",
      "resource_type": "Observation",
      "category": "survey",
      "loinc": "89247-1",
      "name": "ECOG Performance Status",
      "date": "2024-02-09",
      "valueInteger": 1,
      "_rwe": "Baseline functional-status covariate."
    },
    {
      "id": "ecog-2",
      "resource_type": "Observation",
      "category": "survey",
      "loinc": "89247-1",
      "name": "ECOG Performance Status",
      "date": "2024-08-05",
      "valueInteger": 2,
      "_rwe": "Clinical deterioration and endpoint-support signal."
    },
    {
      "id": "img-1",
      "resource_type": "Observation",
      "category": "imaging-summary",
      "date": "2024-08-01",
      "valueCode": "progressive disease",
      "source": "oncology note abstraction",
      "_rwe": "Clinical response component; not RECIST-confirmed unless source report is available."
    }
  ],
  "treatment_failure_non_response": {
    "constructed_endpoint": true,
    "candidate_failure_date": "2024-08-05",
    "classification": "probable treatment failure / non-response",
    "certainty": "moderate",
    "signals": [
      {
        "source_id": "medrx-1",
        "signal": "MedicationRequest stopped for progression"
      },
      {
        "source_id": "medrx-2",
        "signal": "New line of therapy started within 7 days"
      },
      {
        "source_id": "img-1",
        "signal": "Imaging summary says progressive disease"
      },
      {
        "source_id": "ecog-2",
        "signal": "ECOG worsened from 1 to 2"
      },
      {
        "source_id": "enc-3",
        "signal": "Emergency encounter for dyspnea and pleural effusion"
      }
    ],
    "_rwe": "Composite endpoint combining clinical response evidence, treatment-pattern proxy, and intercurrent-event handling."
  },
  "claims_linkage": {
    "payer_type": "commercial",
    "subscriber_id_hash": "sub_44fd19",
    "member_id_hash": "mem_772ac1",
    "enrollment": [
      {
        "start": "2023-12-01",
        "end": "2024-12-31",
        "medical": true,
        "pharmacy": true
      }
    ],
    "claim_refs": [
      {
        "claim_id_hash": "claim_77aa",
        "date": "2024-02-09",
        "setting": "outpatient",
        "hcpcs": "99215",
        "linked_encounter": "enc-2"
      },
      {
        "claim_id_hash": "claim_91fd",
        "date": "2024-07-21",
        "setting": "emergency",
        "revenue_center": "0450",
        "linked_encounter": "enc-3"
      }
    ],
    "_rwe": "Coverage continuity, utilization capture, EHR-claims concordance, and subscriber/member identifier separation."
  },
  "provenance": {
    "source_systems": [
      "synthetic OpenEMR-like EHR",
      "synthetic adjudicated claims"
    ],
    "mapping_version": "oncology-ehr-rwe-map-0.1",
    "source_trace": {
      "line_of_therapy": "MedicationRequest sequence and stop/start dates",
      "treatment_failure_non_response": "Medication status reason, imaging summary, ECOG change, next-line therapy, and ED utilization",
      "claims": "Payer extract line-level claims linked to encounter IDs",
      "ecog": "Structured observation using LOINC 89247-1"
    }
  },
  "data_quality_flags": [
    {
      "flag": "synthetic_record",
      "severity": "info",
      "affects": "all fields"
    },
    {
      "flag": "date_shifted",
      "severity": "info",
      "affects": "calendar-time interpretation"
    },
    {
      "flag": "imaging_not_recist_confirmed",
      "severity": "medium",
      "affects": "treatment_failure_non_response"
    },
    {
      "flag": "claims_ehr_linkage_probabilistic",
      "severity": "medium",
      "confidence": 0.94,
      "affects": "claims_linkage"
    },
    {
      "flag": "oral_adherence_unobserved",
      "severity": "medium",
      "affects": "osimertinib exposure duration"
    }
  ],
  "source_references": [
    {
      "label": "OpenEMR FHIR API documentation",
      "url": "https://github.com/openemr/openemr/blob/master/Documentation/api/FHIR_API.md"
    },
    {
      "label": "HL7 FHIR R4 Encounter",
      "url": "https://hl7.org/fhir/R4/encounter.html"
    },
    {
      "label": "HL7 FHIR R4 Condition",
      "url": "https://hl7.org/fhir/R4/condition.html"
    },
    {
      "label": "HL7 FHIR R4 MedicationRequest",
      "url": "https://hl7.org/fhir/R4/medicationrequest.html"
    },
    {
      "label": "HL7 FHIR R4 Observation",
      "url": "https://hl7.org/fhir/R4/observation.html"
    },
    {
      "label": "mCODE ECOG Performance Status",
      "url": "https://build.fhir.org/ig/HL7/fhir-mCODE-ig/StructureDefinition-mcode-ecog-performance-status.html"
    },
    {
      "label": "FDA Real-World Data guidance",
      "url": "https://www.fda.gov/media/152503/download"
    }
  ]
}